Medtronic Cgm Market Share

Share on facebook

Global Continuous Glucose Monitoring System Market 2016-2022 - Medtronic And Dexcom Are The Only Major Players - Research And Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Continuous Glucose Monitoring System Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022" report to their offering. Tweet this Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from self-monitoring blood glucose devices (SMBG). SMBG devices are cheaper and easy to use and have an less stringent approval process from authorities like FDA. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The Continue reading >>

Share on facebook

Popular Questions

  1. coravh

    Pump market getting smaller

    I just saw this on another site - apparently Animas is getting out of the pump market and will be transitioning their clients to Medtronic. Does that leave only Medtronic and Omnipod as pump providers? I know that when I was FFL, about 80% of pumpers were on pods and the rest appeared mainly to be on a Medtronic pump.

  2. PeterPumper

    That still leaves Tandem, as well, right?
    It seems to me that Animas and Tandem were splitting the remaining market share (both integrate to Dexcom, as opposed to Medtronic which has its own CGM, and OminPod, the only "Pod" pump). It kinda seems like there just wasn't enough to differentiate Animas and Tandem. J&J (owner of Animas) must have decided it wasn't worth the battle for a subset of a subset of the pump market, especially without their own CGM to integrate. Linda makes sense.
    It's a bit sad, though. We lost SNAP a few years ago, as I recall. Even though I love my Medtronic, I want multiple players, pushing each other, both for tech advancement and price competition.

  3. Lostboy

    Why Medtronic though? Animas uses the dexcom. So now I have to give up dexcom and go all Medtronic?
    Sent from my iPhone using Tapatalk

  4. -> Continue reading
read more close

Related Articles

Popular Articles

More in insulin